Study guide

2.2 Heart Failure & Antiarrhythmic Drugs

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

2.2 Heart Failure & Antiarrhythmic Drugs

Key Takeaways Explain This Topic AI

HFrEF rests on four foundational drug classes: an ARNI (or ACE inhibitor/ARB), an evidence-based beta-blocker (carvedilol, bisoprolol, or metoprolol succinate), a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor

When switching from an ACE inhibitor to sacubitril/valsartan, a mandatory 36-hour washout prevents life-threatening angioedema from overlapping ACE and neprilysin inhibition

Digoxin has a narrow therapeutic index (target 0.5-2.0 ng/mL); hypokalemia, hypomagnesemia, and hypercalcemia potentiate toxicity, which presents with nausea, yellow-green visual halos, and almost any arrhythmia

Amiodarone's half-life is weeks long and it causes pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, and corneal deposits; it inhibits warfarin metabolism and raises digoxin levels, so both doses must be reduced

Class Ic agents (flecainide, propafenone) are contraindicated after myocardial infarction or in structural heart disease because the CAST trial showed increased mortality

Last updated: August 2026

Pharmacologic Foundations of HFrEF

Modern management of heart failure with reduced ejection fraction (HFrEF) rests on four drug classes, each with proven mortality benefit - often called the "four pillars":

1. ARNI: Sacubitril/Valsartan

Sacubitril/valsartan combines the neprilysin inhibitor sacubitril with the ARB valsartan. Neprilysin degrades natriuretic peptides (which promote natriuresis, vasodilation, and anti-remodeling effects); inhibiting it raises natriuretic peptide levels. Because neprilysin inhibition alone also raises angiotensin II, an ARB is co-formulated. In the PARADIGM-HF trial, sacubitril/valsartan reduced cardiovascular death and heart-failure hospitalization by about 20% versus enalapril.

The critical exam point is the 36-hour washout : when switching a patient from an ACE inhibitor to sacubitril/valsartan, stop the ACE inhibitor and wait 36 hours before the first dose. Overlapping ACE and neprilysin inhibition dramatically raises bradykinin and the risk of angioedema . The combination is contraindicated with any ACE inhibitor, in pregnancy, and after prior angioedema. Main adverse effects: hypotension, hyperkalemia, and renal impairment.

2. Evidence-Based Beta-Blockers

Only three beta-blockers carry mortality evidence in HFrEF: carvedilol, bisoprolol, and metoprolol succinate (the extended-release form - metoprolol tartrate and atenolol are not evidence-based for HFrEF). They block chronic sympathetic overstimulation, reducing mortality by roughly a third. Initiate only in stable, euvolemic patients, start low and uptitrate slowly, and expect possible transient worsening of congestion during initiation. Do not start during acute decompensated heart failure.

3. Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone (RALES) and eplerenone (EPHESUS, EMPHASIS-HF) block aldosterone's sodium-retaining and pro-fibrotic effects. The practical limits are hyperkalemia and renal function : avoid starting when serum potassium exceeds 5.0 mEq/L or eGFR is below 30 mL/min, and recheck potassium and creatinine within the first week and periodically thereafter - especially in patients also on ACE inhibitors, ARBs, or ARNIs. Spironolactone causes gynecomastia in about 10% of men through anti-androgen activity; eplerenone is more receptor-selective and spares this effect.

4. SGLT2 Inhibitors

Dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) reduce heart-failure hospitalization and cardiovascular death in HFrEF regardless of diabetes status . Counsel about genital mycotic infections, volume depletion, and the rare but serious euglycemic diabetic ketoacidosis .

Symptomatic and Add-On Agents

Loop diuretics (furosemide, torsemide, bumetanide) relieve congestion and improve symptoms but have no mortality benefit - titrate to the lowest dose that maintains euvolemia.

Digoxin inhibits the membrane Na+/K+-ATPase , raising intracellular sodium, which reduces Na+/Ca2+ exchange and raises intracellular calcium - a positive inotropic effect. Vagomimetic effects slow AV nodal conduction, making digoxin useful for rate control in atrial fibrillation, particularly when blood pressure limits other agents. It reduces hospitalizations but not mortality.

Digoxin has a narrow therapeutic index : the traditional therapeutic range is 0.5-2.0 ng/mL , with many HF clinicians targeting 0.5-0.9 ng/mL. Draw levels at least 6 hours post-dose (ideally 6-12 hours) to allow distribution. Toxicity presents with:

  • GI: nausea, vomiting, anorexia
  • Visual/neurologic: blurred vision, yellow-green halos (xanthopsia) , confusion

Cardiac: virtually any arrhythmia - classically atrial tachycardia with AV block, or bidirectional ventricular tachycardia

Toxicity is potentiated by hypokalemia, hypomagnesemia, hypercalcemia , renal impairment, and hypothyroidism - a thiazide or loop diuretic causing hypokalemia can push a stable digoxin patient into toxicity. Amiodarone, verapamil, quinidine, and macrolide antibiotics raise digoxin concentrations (P-glycoprotein inhibition); reduce the digoxin dose, by about half with amiodarone. Digoxin is renally cleared, so reduce dosing in CKD and the elderly. Life-threatening toxicity is treated with digoxin immune Fab fragments.

Hydralazine plus isosorbide dinitrate combines an arterial and a venous vasodilator. It improved outcomes in self-identified Black patients with HFrEF (A-HeFT) and is an alternative when ACE inhibitors, ARBs, and ARNIs are not tolerated (e.g., advanced renal dysfunction or refractory hyperkalemia). Hydralazine can cause drug-induced lupus and reflex tachycardia; the nitrate component causes headache and tolerance (see section 2.3).

Antiarrhythmics: Vaughan-Williams Classification

Class Mechanism Agents Notes

Ia Moderate Na+ block, prolongs QT Quinidine, procainamide, disopyramide Quinidine: cinchonism, thrombocytopenia; procainamide: lupus

Ib Weak Na+ block, shortens AP Lidocaine, mexiletine Preferentially acts on ischemic tissue; IV lidocaine for VT

Ic Marked Na+ block, no QT effect Flecainide, propafenone Contraindicated post-MI/structural heart disease (CAST trial)

II Beta-blockade Metoprolol, propranolol, esmolol Reduce AV nodal conduction; post-MI benefit

III K+ channel block, prolongs QT Amiodarone, sotalol, dofetilide, ibutilide Torsades risk (except low with amiodarone)

IV Non-DHP Ca2+ block Verapamil, diltiazem AV-nodal slowing; avoid in HFrEF

The Cardiac Arrhythmia Suppression Trial (CAST) is a favorite exam fact: flecainide and encainide suppressed ventricular ectopy after myocardial infarction but increased mortality . Hence Class Ic agents are reserved for patients without structural or ischemic heart disease (e.g., selected paroxysmal AF "pill-in-pocket" use).

Amiodarone Deep Dive

Amiodarone is a Class III agent with properties of all four Vaughan-Williams classes and is effective for atrial and ventricular arrhythmias. It is a structural analogue of thyroxine, about 37% iodine by weight, with an enormous volume of distribution and a half-life of roughly 40-55 days - loading doses are needed, and effects persist for weeks after stopping.

Organ toxicities to memorize:

Pulmonary fibrosis/pneumonitis - the most serious; baseline chest X-ray and pulmonary function tests, with evaluation of any new dyspnea or cough

Thyroid dysfunction - both hypothyroidism (common) and amiodarone-induced thyrotoxicosis; check TSH at baseline and every 6 months

  • Hepatotoxicity - monitor liver enzymes
  • Corneal microdeposits - nearly universal, usually benign; eye exam if visual symptoms
  • Photosensitivity and blue-gray skin discoloration
  • Bradycardia and QT prolongation - despite prolonging the QT, amiodarone has a relatively low torsades risk

Key interactions: amiodarone inhibits CYP2C9 and P-glycoprotein , so it potentiates warfarin (reduce the warfarin dose by roughly 25-30% and monitor INR closely) and raises digoxin levels (reduce digoxin by ~50%). Avoid combining with other QT-prolonging drugs.

Adenosine

Adenosine is an endogenous nucleoside that activates A1 receptors, producing transient AV nodal blockade - it is the drug of choice for terminating paroxysmal supraventricular tachycardia (SVT) . Give it as a rapid IV push followed by a fast saline flush because its half-life is under 10 seconds . Patients experience brief flushing, chest pressure, dyspnea, and a moment of asystole - warn them beforehand. Use caution in asthma (bronchospasm) and avoid in high-degree AV block. Effects are antagonized by methylxanthines (caffeine, theophylline) and potentiated by dipyridamole .